MT-2 MT1 5 mg/vial raw powder 99%

Mt-2

melanotan-II;Melanotan II;MT-II;Melanotan (MT)-II;Melatonan;Melanotan II acetate salt;CHEMBL430239;(3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide;L-Lysinamide, N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-7)-peptide

121062-08-6

C50H69N15O9

JDKLPDJLXHXHNV-MFVUMRCOSA-N

1024.18

1023.540283

1308068-626-2

UPF5CJ93X7

DTXSID90153135

Polypeptide

382.26000

-1.27

white solid

1.4±0.1 g/cm3

1.683

H2O: 5 mg/mL, soluble

−20°C

Synthetic cyclic heptapeptide / non-selective melanocortin receptor agonist

Research compound — NOT FDA approved. FDA issued warning letters. WADA banned substance.

A synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) analog of α-MSH. Melanotan II is a high-affinity non-selective agonist at MC1R, MC3R, MC4R, and MC5R. MC1R activation induces melanogenesis (skin darkening/tanning); MC4R activation affects sexual function, appetite suppression, and energy homeostasis. Carries significant safety risks including nausea, hypertension, and priapism.

1.2 nM

1.0 nM

1.1 nM

2.1 nM

Wikberg JES, et al. Pharmacol Res. 2000;42(5):393–420. PubChem CID 92432.DOI

NCT00005114

CHEMBL363210

PubChem

FDA Warning Letters: Melanotan II (unapproved drug); WADA Prohibited List: Melanotan II (S2 hormone modulator)

Melanotan II is NOT FDA-approved. The FDA has issued multiple warning letters to companies illegally selling Melanotan II as an unapproved new drug. It is also listed on the WADA Prohibited List as a banned substance in sport. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.